Search results
Results from the WOW.Com Content Network
This category is for initial public offerings, by year. Subcategories. This category has the following 35 subcategories, out of 35 total. 0–9.
You can often tell the health of the stock market by the number and performance of initial public offerings, or IPOs. As 2022 has seen a bear market in the major averages, it's not surprising at ...
CG Oncology's initial public offering (IPO), the first by a biotech firm this year, (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on ...
This IPO Biotech Stock Could Be the Next Eli Lilly. Alex Carchidi, The Motley Fool. October 3, 2024 at 9:05 AM. Eli Lilly's (NYSE: LLY) stock is up by more than 736% over the last five years ...
This was the largest Canadian biotech IPO in more than a decade. [5] By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across ...
PDL made another public offering in 2000, at the peak of the biotech IPO window that ran from 1998 to 2001. [ 7 ] [ 11 ] In 2003 it settled litigation with Genentech over royalty payments owed to PDL under their license agreement; annual royalties were anticipated at that time to be around $90M per year. [ 12 ]
The IPO raised $604.3 million and eclipsed the $373 million raised by Allogene Therapeutics in October, which is the largest biotech since Axovant Sciences' $363 million IPO in 2015.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.